Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
M.J. Molina-Garrido, C. Guillen-Ponce and A. Mora-Rufete
Affiliation: Consulta de Cancer en el Anciano, Seccion de Oncologia Medica, Hospital General Virgen de la Luz in Cuenca, Hermandad Donantes de Sangre Street, Cuenca, Spain.
Keywords: Adjuvant Online, aging, anit-HER2 therapy, breast cancer, cardiotoxicity, chemotherapy, comorbidity, Comprehensive Geriatric
Assessment, elderly women, histology, HER2 positive, lapatinib, St Gallen criteria, targeted therapy, trastuzumab.
Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human
epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have
been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this
subgroup. This article has reviewed the main articles that have analyzed these items.
Rights & PermissionsPrintExport